Literature DB >> 24084446

Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms.

M Introna1, J Golay, A Rambaldi.   

Abstract

Cytokine Induced Killer (CIK) cells are in vitro activated human CD8 T cells which have maintained several characteristics of T-EMRA cells and additionally acquired non specific anti tumoral cytotoxicity and CD56 overexpression, thus representing a cell population with double T and NK phenotype. Due to their in vivo intratumoral homing and lack of Graft versus Host (GVH) reactivity, CIK cells have been extensively used in cancer patients either in autologous or allogeneic contexts. Here we summarise CIK main biological features as well as their most prominent clinical results.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokine Induced Killer (CIK) cells; Haematologic neoplasms; Hematopoietic stem cells transplantation

Mesh：

Substances：

Year:  2013        PMID： 24084446     DOI： 10.1016/j.imlet.2013.09.017

Source DB:  PubMed          Journal:  Immunol Lett        ISSN： 0165-2478            Impact factor:   3.685


  18 in total

1.  Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.

Authors:  Tao Lin; Chun Song; Dong-Yu Chuo; Hao Zhang; Jian Zhao
Journal:  Tumour Biol       Date:  2015-10-24

2.  Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

Authors:  Giulia Mesiano; Roberta Zini; Giulia Montagner; Nicoletta Bianchi; Rossella Manfredini; Antonella Chillemi; Massimo Aglietta; Giovanni Grignani; Ilaria Lampronti; Erika Fiorino; Fabio Malavasi; Dario Sangiolo; Roberto Gambari; Davide Ferrari
Journal:  Mol Med       Date:  2017-08-09       Impact factor: 6.354

3.  Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity in vitro.

Authors:  Jingsong Cao; Cong Chen; Yuhuan Wang; Xuecheng Chen; Zeying Chen; Xiaoling Luo
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

4.  Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.

Authors:  Xia Zhao; Chun-Yan Ji; Guo-Qiang Liu; Dao-Xin Ma; Hui-Fang Ding; Min Xu; Jian Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 5.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.

Authors:  Yu-Peng Hong; Zi-Duo Li; Pankaj Prasoon; Qi Zhang
Journal:  World J Hepatol       Date:  2015-05-08

Review 6.  Harnessing the immune system to improve cancer therapy.

Authors:  Nikos E Papaioannou; Ourania V Beniata; Panagiotis Vitsos; Ourania Tsitsilonis; Pinelopi Samara
Journal:  Ann Transl Med       Date:  2016-07

7.  More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.

Authors:  Peter Bader; Emilia Salzmann-Manrique; Adriana Balduzzi; Jean-Hugues Dalle; Ann E Woolfrey; Merav Bar; Michael R Verneris; Michael J Borowitz; Nirali N Shah; Nathan Gossai; Peter J Shaw; Allen R Chen; Kirk R Schultz; Hermann Kreyenberg; Lucia Di Maio; Gianni Cazzaniga; Cornelia Eckert; Vincent H J van der Velden; Rosemary Sutton; Arjan Lankester; Christina Peters; Thomas E Klingebiel; Andre M Willasch; Stephan A Grupp; Michael A Pulsipher
Journal:  Blood Adv       Date:  2019-11-12

8.  Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Authors:  Paola Circosta; Angela Rita Elia; Indira Landra; Rodolfo Machiorlatti; Maria Todaro; Sabrina Aliberti; Davide Brusa; Silvia Deaglio; Sabina Chiaretti; Riccardo Bruna; Daniela Gottardi; Massimo Massaia; Filomena Di Giacomo; Anna Rita Guarini; Robin Foà; Peter W Kyriakides; Rohan Bareja; Olivier Elemento; Gurunadh R Chichili; Emanuele Monteleone; Paul A Moore; Syd Johnson; Ezio Bonvini; Alessandro Cignetti; Giorgio Inghirami
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

9.  CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.

Authors:  Valeria Leuci; Chiara Donini; Giovanni Grignani; Ramona Rotolo; Giulia Mesiano; Erika Fiorino; Loretta Gammaitoni; Lorenzo D'Ambrosio; Alessandra Merlini; Elisa Landoni; Enzo Medico; Sonia Capellero; Lidia Giraudo; Giulia Cattaneo; Ilenia Iaia; Ymera Pignochino; Marco Basiricò; Elisa Vigna; Alberto Pisacane; Franca Fagioli; Soldano Ferrone; Massimo Aglietta; Gianpietro Dotti; Dario Sangiolo
Journal:  Clin Cancer Res       Date:  2020-09-08       Impact factor: 12.531

Review 10.  Mechanisms and applications of interleukins in cancer immunotherapy.

Authors:  Doxakis Anestakis; Savvas Petanidis; Spyridon Kalyvas; Christiane M Nday; Olga Tsave; Efrosini Kioseoglou; Athanasios Salifoglou
Journal:  Int J Mol Sci       Date:  2015-01-13       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.